LY3435151 + pembrolizumab

LY3435151 + pembrolizumab is an investigational combination therapy for advanced solid tumors. LY3435151 is a monoclonal antibody targeting CD226, designed to enhance antitumor immune responses by activating T cells. Pembrolizumab is a monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), restoring T cell activity against tumors. This combination aims to improve antitumor immunity by simultaneously activating T cells via CD226 and releasing inhibitory PD-1-mediated immune checkpoints. The combination was evaluated in a Phase 1a/1b clinical trial in multiple solid tumor types including triple-negative breast cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma, and others[1][3].

Other names

LY 3435151LY3435151LY-3435151